You can buy or sell Varian and other stocks, options, ETFs, and crypto commission-free!
Varian Medical Systems, Inc. engages in the manufacture of medical devices and software for treating cancer and other medical conditions. It operates through the Oncology Systems and Proton Solutions segments. Read More The Oncology Systems segment designs, manufactures, sells, and services hardware and software products for treating cancer with conventional radiation therapy, and advanced treatments. The Proton Solutions segment delivers proton therapy, a form of external beam radiotherapy using proton beams for the treatment of cancer. The company was founded by William Hansen, Edward Ginzton, Russell Varian, and Sigurd Varian in 1948 and is headquartered in Palo Alto, CA.
Palo Alto, California
52 Week High
52 Week Low
Global Proton Therapy Market Outlook 2019-2025: Market is Highly Consolidated with Three Major Players - IBA Proton Therapy, Varian Medical Systems and Hitachi
DUBLIN, March 20, 2019 /PRNewswire/ -- The "Global Proton Therapy Market (By Product - Equipment & Services; By Room Type - Single Room & Multi Room; By Region - North America, Asia Pacific & Europe) Market Outlook 2025" report has been added to ResearchAndMarkets.
Stock Under Review: Varian Medical Systems (NYSE: VAR)
Varian Medical Systems trades as part of the healthcare sector and is in the medical instruments and equipment industry. Varian Medical Systems Inc is engaged in the healthcare sector. It manufactures medical devices for conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy. Previous Intraday Trading Performance: The VAR stock showed a previous change of -0.75% with an open at 136.85 and a close of 135.57. It reached an intraday high of 136.85 and a low of 133.99. PR Newswire: Vari...
Yahoo FinanceMar 13
HOLX vs VAR: Which MedTech Stock is a Better Investment Pick?
Hologic, Inc. HOLX and Varian Medical Systems, Inc. VAR are solid contenders in the U.S. MedTech space, which is expected to reach $409.5 billion worth by 2023 at a CAGR of 4.5%. Analysts believe that 2019 will prove profitable for the U.S. medical device companies, courtesy of a 2.3% Medical Device tax abatement along with focus on AI and cybersecurity. Meanwhile, it is difficult to make a choice between the above-mentioned Medical instrument companies as both currently carry a Zacks Rank #2 (Buy). You ca...
Available Apr 24, After Hours